Drug profile · INN
onasemnogene abeparvovec
ZOLGENSMA
onasemnogene abeparvovec (ZOLGENSMA) is a survival motor neuron protein exogenous gene. Associated with Novartis Pharmaceuticals.
Drug details — onasemnogene abeparvovec
- Class
- Musculo-skeletal system (M09)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
onasemnogene abeparvovec (ZOLGENSMA) is a survival motor neuron protein exogenous gene. Associated with Novartis Pharmaceuticals.
Key facts
Mechanism of action
Survival motor neuron protein exogenous gene
Primary target: Survival motor neuron protein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
EMA Issues Positive Opinion for Itvisma (Onasemnogene Abeparvovec) Gene Therapy for Spinal Muscular Atrophy
European Medicines Agency issues positive opinion for Itvisma, a one-time gene therapy for spinal muscular atrophy in infants and children.
Gene Therapies for SMA: FDA Market Analysis & Future Outlook 2024
This article delves into the FDA market analysis of gene therapies for Spinal Muscular Atrophy (SMA), focusing on Zolgensma and its future in 2024.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is onasemnogene abeparvovec?
onasemnogene abeparvovec (ZOLGENSMA) is a survival motor neuron protein exogenous gene. Associated with Novartis Pharmaceuticals.
What is the brand name for onasemnogene abeparvovec?
ZOLGENSMA is a marketed brand name for onasemnogene abeparvovec. Check FDA Drugs@FDA for the current US label holder and prescribing information.